We've detected that Javascript is not enabled. It is required for an optimal survey taking experience.
Please check your browser's settings and make sure Javascript is turned on. Learn how to enable Javascript.

Skip survey header

Novo Nordisk Obesity Product Theater Evaluation SBHPP Las Vegas, November 11

1. I am a(n):

PRESENTATION

1 = Strongly Disagree, 4 = Neutral, 7 = Strongly Agree
* Required Field

2. The speaker was knowledgeable about the content. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

3. The speaker was engaging and delivered the presentation clearly and effectively. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

ACTIONS
As a result of this program, I intend to:

1 = Strongly Disagree, 4 = Neutral, 7 = Strongly Agree
* Required Field

4. Consider this GLP-1 RA as a treatment option in appropriate patients. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

5. Initiate this GLP-1 RA in appropriate patients. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

6. Consider the different dose and formulation options available when discussing this GLP-1 RA with patients.
*This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

OBJECTIVES
As a result of this program, I have a better understanding of:

1 = Strongly Disagree, 4 = Neutral, 7 = Strongly Agree
* Required Field

7. Obesity as a chronic disease tied to excess adiposity. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

8. The common assumptions about health in people with excess adiposity, including those with overweight. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

9. The efficacy and safety of this GLP-1 RA, including data from chronic weight management trials, a CVOT, and a complementary real-world study. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

10. The role of each dose and formulation option within the overall treatment portfolio. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

OVERALL

1 = Strongly Disagree, 4 = Neutral, 7 = Strongly Agree
* Required Field

11. My interest in learning about this topic and/or other topics related to it has increased as a result of attending this program. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

12. I will apply and incorporate what I learned from this program into my own practice. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

INTEREST
Please check the box accordingly:

* Required Field

13. I am interested in learning more about weight-related comorbidities associated with obesity. *This question is required.

Yes	No